scholarly journals Factors affecting surgical site infection rate after elective gastric cancer surgery

2016 ◽  
Vol 32 (3) ◽  
pp. 178-184 ◽  
Author(s):  
Tolga Ozmen ◽  
Mirkhalig Javadov ◽  
Cumhur S. Yegen
2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e15576-e15576
Author(s):  
K. Inoue ◽  
H. Imamura ◽  
Y. Kimura ◽  
K. Fujitani ◽  
Y. Miyake ◽  
...  

e15576 Background: In Japan, antimicrobial prophylaxis (AMP) is typically administered for 3 to 4 days postoperatively in gastric cancer surgery. This far exceeds the recommended 24h or less laid out by the Centers for Disease Control (CDC) guidelines for the prevention of surgical-site infections, after a clean-contaminated operation. Methods: A multicenter randomized phase III trial was designed to evaluate the effect of postoperative AMP in gastric cancer surgery. Patients (pts) were required to have histologically proven gastric cancer which was curable by distal gastrectomy, be classifiable as ASA 1 or 2, and have adequate organ function. Pts were randomized to: (A) perioperative AMP (cefazolin 1g, at <30min before incision, every 3h intraoperative supplements) plus postoperative AMP (cefazolin 1g, twice daily for 2 postoperative days) or (B) perioperative AMP alone. Pts were stratified by institution and ASA. The primary endpoint was the incidence of surgical site infection (SSI). With 171 pts per arm, this study had 80% power to demonstrate non-inferiority with 5% margin of peri-AMP alone and 0.05 1-sided alpha. Results: 355 patients were recruited (A: 179, B: 176) in 7 centers between June 2005 and December 2007. The surgical-site infection rate was 9.0 percent (16 of 178) for peri-/post AMP and 4.5 percent (8 of 176) for peri-AMP alone, with no significant differences (Fisher's exact test: P=0.14, RR=1.98 [95%CI, 0.89–4.44]), but showing a significant non-inferiority (P<0.001). The remote site infection rate was 3.4 percent (6 of 178) for peri-/post AMP and 5.1 percent (9 of 175) for peri-AMP alone, with no significant differences (P=0.44, RR=0.66 [95%CI, 0.25- 1.70]). Conclusions: This multicenter randomized phase III trial confirms that postoperative AMP is unnecessary in patients undergoing distal gastrectomy for gastric cancer. No significant financial relationships to disclose.


Medicine ◽  
2019 ◽  
Vol 98 (32) ◽  
pp. e16739
Author(s):  
Jung Ho Kim ◽  
Jinnam Kim ◽  
Woon Ji Lee ◽  
Hye Seong ◽  
Heun Choi ◽  
...  

2015 ◽  
Vol 32 (6) ◽  
pp. 472-479 ◽  
Author(s):  
Hideki Ushiku ◽  
Kei Hosoda ◽  
Keishi Yamashita ◽  
Natsuya Katada ◽  
Shiro Kikuchi ◽  
...  

2020 ◽  
Author(s):  
Tolga Olmez ◽  
Selcuk Gulmez ◽  
Erdal Karakose ◽  
Cem Batuhan Ofluoglu ◽  
Aziz Serkan Senger ◽  
...  

2014 ◽  
Vol 87 (6) ◽  
pp. 311 ◽  
Author(s):  
Kuk Hyun Jung ◽  
Seung Jong Oh ◽  
Kang Kook Choi ◽  
Su Mi Kim ◽  
Min Gew Choi ◽  
...  

2007 ◽  
Vol 67 (2) ◽  
pp. 127-134 ◽  
Author(s):  
C.M. Couris ◽  
M. Rabilloud ◽  
R. Ecochard ◽  
M.H. Metzger ◽  
E. Caillat-Vallet ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document